A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

Keiichi Fujiwara; Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Nagio Takigawa; Katsuyuki Hotta; Shigeki Umemura; Keisuke Sugimoto; Takuo Shibayama; Haruhito Kamei; Shingo Harita; Niro Okimoto; Mitsune Tanimoto

doi:10.1007/s00280-005-0117-1

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

Keiichi Fujiwara, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Katsuyuki Hotta, Shigeki Umemura, Keisuke Sugimoto, Takuo Shibayama, Haruhito Kamei, Shingo Harita, Niro Okimoto, Mitsune Tanimoto

University Hospital

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Purpose: The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients and methods: Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1-3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m²/day, while cisplatin was fixed at the dose of 20 mg/m²/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Results: Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m²/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m²/day with cisplatin 20 mg/m²/ day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. Conclusion: The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.

Original language	English
Pages (from-to)	755-760
Number of pages	6
Journal	Cancer Chemotherapy and Pharmacology
Volume	57
Issue number	6
DOIs	https://doi.org/10.1007/s00280-005-0117-1
Publication status	Published - Jun 2006

Keywords

3-day schedule
Cisplatin
Elderly patients
Phase I study
Small-cell lung cancer
Topotecan

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-005-0117-1

Cite this

@article{07653eb6cb4a4f94bcebf95e4a0c49dc,

title = "A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer",

abstract = "Purpose: The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients and methods: Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1-3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m2/day, while cisplatin was fixed at the dose of 20 mg/m2/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Results: Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m2/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m2/day with cisplatin 20 mg/m2/ day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. Conclusion: The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.",

keywords = "3-day schedule, Cisplatin, Elderly patients, Phase I study, Small-cell lung cancer, Topotecan",

author = "Keiichi Fujiwara and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Nagio Takigawa and Katsuyuki Hotta and Shigeki Umemura and Keisuke Sugimoto and Takuo Shibayama and Haruhito Kamei and Shingo Harita and Niro Okimoto and Mitsune Tanimoto",

year = "2006",

month = jun,

doi = "10.1007/s00280-005-0117-1",

language = "English",

volume = "57",

pages = "755--760",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

AU - Fujiwara, Keiichi

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Hotta, Katsuyuki

AU - Umemura, Shigeki

AU - Sugimoto, Keisuke

AU - Shibayama, Takuo

AU - Kamei, Haruhito

AU - Harita, Shingo

AU - Okimoto, Niro

AU - Tanimoto, Mitsune

PY - 2006/6

Y1 - 2006/6

N2 - Purpose: The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients and methods: Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1-3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m2/day, while cisplatin was fixed at the dose of 20 mg/m2/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Results: Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m2/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m2/day with cisplatin 20 mg/m2/ day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. Conclusion: The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.

AB - Purpose: The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients and methods: Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1-3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m2/day, while cisplatin was fixed at the dose of 20 mg/m2/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Results: Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m2/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m2/day with cisplatin 20 mg/m2/ day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. Conclusion: The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.

KW - 3-day schedule

KW - Cisplatin

KW - Elderly patients

KW - Phase I study

KW - Small-cell lung cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=33645729834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645729834&partnerID=8YFLogxK

U2 - 10.1007/s00280-005-0117-1

DO - 10.1007/s00280-005-0117-1

M3 - Article

C2 - 16208519

AN - SCOPUS:33645729834

SN - 0344-5704

VL - 57

SP - 755

EP - 760

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 6

ER -

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this